Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has said Leopoldo Zambeletti is relinquishing his independent directorship of the company to take on a senior business development role at the firm.
This strategic move will allow Zambeletti to fully focus on facilitating prospective partnerships for the future plans of bexmarilimab, the company's flagship cancer therapeutic.
"I am pleased that Leopoldo will be supporting our continued engagement with potential partners to support future plans for bexmarilimab," said Faron CEO Markku Jalkanen in a statement.
"He brings extensive experience within the life science industry, and his expertise will be invaluable as Faron continues the development of bexmarilimab," the Faron CEO added.
Zambeletti led the European Healthcare Investment team at JP Morgan for eight years before serving in the same role at Credit Suisse for an additional five years.